AU2007304439A1 - Treatment for non-alcoholic-steatohepatitis - Google Patents

Treatment for non-alcoholic-steatohepatitis Download PDF

Info

Publication number
AU2007304439A1
AU2007304439A1 AU2007304439A AU2007304439A AU2007304439A1 AU 2007304439 A1 AU2007304439 A1 AU 2007304439A1 AU 2007304439 A AU2007304439 A AU 2007304439A AU 2007304439 A AU2007304439 A AU 2007304439A AU 2007304439 A1 AU2007304439 A1 AU 2007304439A1
Authority
AU
Australia
Prior art keywords
substituted
group
aryl
independently selected
heterocycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007304439A
Other languages
English (en)
Other versions
AU2007304439A2 (en
Inventor
Naiara Beraza
Michel Dreano
Christian Trautwein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ares Trading SA
Original Assignee
Ares Trading SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading SA filed Critical Ares Trading SA
Publication of AU2007304439A1 publication Critical patent/AU2007304439A1/en
Publication of AU2007304439A2 publication Critical patent/AU2007304439A2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2007304439A 2006-10-04 2007-10-04 Treatment for non-alcoholic-steatohepatitis Abandoned AU2007304439A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US84925106P 2006-10-04 2006-10-04
US60/849,251 2006-10-04
US90411607P 2007-02-28 2007-02-28
US60/904,116 2007-02-28
PCT/EP2007/008627 WO2008040548A2 (en) 2006-10-04 2007-10-04 Treatment for non-alcoholic-steatohepatitis

Publications (2)

Publication Number Publication Date
AU2007304439A1 true AU2007304439A1 (en) 2008-04-10
AU2007304439A2 AU2007304439A2 (en) 2009-04-23

Family

ID=38949734

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007304439A Abandoned AU2007304439A1 (en) 2006-10-04 2007-10-04 Treatment for non-alcoholic-steatohepatitis

Country Status (7)

Country Link
US (1) US20080194575A1 (cg-RX-API-DMAC7.html)
EP (1) EP2157975A2 (cg-RX-API-DMAC7.html)
JP (1) JP2010505783A (cg-RX-API-DMAC7.html)
AU (1) AU2007304439A1 (cg-RX-API-DMAC7.html)
CA (1) CA2664413A1 (cg-RX-API-DMAC7.html)
IL (1) IL197941A0 (cg-RX-API-DMAC7.html)
WO (1) WO2008040548A2 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008011216A2 (en) 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
US8524212B2 (en) * 2007-10-24 2013-09-03 Mitsubishi Tanabe Pharma Corporation Prophylactic and/or therapeutic drug for nonalcoholic steatohepatitis
US20100008988A1 (en) * 2008-07-14 2010-01-14 Glenmark Generics, Ltd. Tablet compositions of amine polymers
US20120202849A1 (en) * 2009-10-12 2012-08-09 Anil Pareek Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease
AU2011260323A1 (en) 2010-06-04 2012-11-15 F. Hoffmann-La Roche Ag Aminopyrimidine derivatives as LRRK2 modulators
KR101566091B1 (ko) 2010-11-10 2015-11-04 에프. 호프만-라 로슈 아게 Lrrk2 조절제로서 피라졸 아미노피리미딘 유도체
US8865641B2 (en) 2011-06-16 2014-10-21 The Feinstein Institute For Medical Research Methods of treatment of fatty liver disease by pharmacological activation of cholinergic pathways
CA2848711C (en) * 2011-09-16 2019-08-06 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
TWI696462B (zh) * 2013-07-10 2020-06-21 日商興和股份有限公司 非酒精性脂肪性肝疾病治療劑
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
CA2941411A1 (en) * 2014-03-21 2015-09-24 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of fibrosis
CA2968215A1 (en) * 2014-08-20 2016-02-25 Yale University Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss
CN105267953B (zh) * 2015-09-15 2018-08-31 浙江大学 Dll4细胞因子在制备治疗暴发性肝功能衰竭药剂中的应用
EP3445450A4 (en) * 2016-04-21 2020-01-08 CSL Limited METHOD FOR TREATING OR PREVENTING LIVER DISEASES
US20170319540A1 (en) * 2016-05-06 2017-11-09 Vivus, Inc. Methods and Compositions for the Treatment of Non-Alcoholic Steatohepatitis
EP3278802A1 (en) * 2016-08-04 2018-02-07 Metabolys New treatment for the non alcoholic steatohepatitis and fibrosis
GB201614455D0 (en) 2016-08-24 2016-10-05 Univ Oxford Innovation Ltd Biomarkers
TW201818964A (zh) * 2016-09-30 2018-06-01 瑞士商諾伊曼特醫療公司 使用色胺酸羥化酶抑制劑之方法
US20190351003A1 (en) * 2017-02-07 2019-11-21 The Regents Of The University Of California Methods for inhibiting nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, and/or de novo lipogenesis
JPWO2020090967A1 (ja) * 2018-10-31 2021-09-16 東和薬品株式会社 線維化誘導遺伝子の発現抑制剤およびその用途
WO2021073643A1 (zh) * 2019-10-18 2021-04-22 正大天晴药业集团股份有限公司 用于治疗非酒精性脂肪性肝炎的药物
CN113087757A (zh) * 2021-03-12 2021-07-09 济南大学 一种5α结构的乙型强心苷的制备及其抗肝癌应用
KR102684334B1 (ko) * 2021-08-18 2024-07-12 제이투에이치바이오텍 (주) 지방간염, 지방증 또는 섬유증의 예방 또는 치료용 복합 제제

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US7122544B2 (en) * 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
US7429599B2 (en) * 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
US7129242B2 (en) * 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
WO2002085396A1 (en) * 2001-04-24 2002-10-31 President And Fellows Of Harvard College Inhibition of jun kinase
CA2512879A1 (en) * 2003-01-17 2004-08-12 Soumya P. Sahoo N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
US20050266391A1 (en) * 2004-01-15 2005-12-01 Bennett Brydon L Methods for preserving tissue
WO2007035703A1 (en) * 2005-09-20 2007-03-29 Schering Corporation 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4 , 5-b] pyridin-3-yl] piperidine useful as histamine h3 antagonist

Also Published As

Publication number Publication date
WO2008040548A2 (en) 2008-04-10
CA2664413A1 (en) 2008-04-10
IL197941A0 (en) 2009-12-24
EP2157975A2 (en) 2010-03-03
WO2008040548A3 (en) 2009-05-22
US20080194575A1 (en) 2008-08-14
JP2010505783A (ja) 2010-02-25
AU2007304439A2 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
AU2007304439A2 (en) Treatment for non-alcoholic-steatohepatitis
KR102699958B1 (ko) 엘라피브라노르와 같은 ppar 작용제 및 아세틸-coa 카르복실라아제 (acc) 저해제를 포함하는 조합
ES2959842T3 (es) Combinación de un agonista de PPAR con un agonista de FXR
DK2582683T3 (en) TREATMENT OF Gout and Hyperuricemia
Xu et al. Canagliflozin ameliorates nonalcoholic fatty liver disease by regulating lipid metabolism and inhibiting inflammation through induction of autophagy
RU2684106C2 (ru) Фармацевтические комбинации
CA2794798C (en) Treatment of gout
AU2018233975A1 (en) Pharmaceutical compositions for combination therapy
KR20160079124A (ko) 동질접합성 가족성 과콜레스테롤증의 치료
US20200155650A1 (en) Combination treatment of NAFLD and NASH
TW201136916A (en) New uses
JP2015511632A (ja) メラノーマの治療におけるraf阻害剤およびmek阻害剤の投与
Ouyang et al. A natural compound jaceosidin ameliorates endoplasmic reticulum stress and insulin resistance via upregulation of SERCA2b
JP2009545547A (ja) 鉄キレーターを使用した内分泌機能不全の処置
CN104039148A (zh) 组合als疗法
WO2025158405A1 (en) Methods of improving glycemic control with a menin inhibitor
EP3784650B1 (en) N-phenyl-n'-(4-{[6-(1h-imidazol-1-yl)-4-pyrimidinyl]amino}phenyl)urea derivatives as mct4 inhibitors for the treatment of cancer
US20220273593A1 (en) Compounds and compositions for treating kidney disease
CN114401745A (zh) 包含fxr激动剂的治疗
Gray et al. NAD (P) H oxidase isoforms as therapeutic targets for diabetic complications
KR20210015849A (ko) 트로피펙소르 및 세니크리비록을 포함하는 조합물
AU2002366975B2 (en) Quinazolinone compounds in combined modalities for improved cancer treatment
TW202539665A (zh) Fgfr4抑制劑與ppar促效劑之組合
US20130095059A1 (en) Inhaled no donor kmups derivative preventing allergic pulmonary vascular and bronchial inflammation via suppressed cytokines, inos and inflammatory cell counts in asthma model

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 31 MAR 2009

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application